产品
编 号：F751930
分子式：C13H17Cl2N3O5S
分子量：398.26
分子式：C13H17Cl2N3O5S
分子量：398.26
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2387898-69-1
产品详情
生物活性：
PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD).
体内研究：
PBT434 methanesulfonate (30 mg/kg；口服；每日一次，持续 21 天) 显着保留了 6-OHDA 毒模型中的神经元数量，并在 L-DOPA 模型中显示出明显更少的旋转，显着减少了 MPTP 模型中的 SNpc 神经元损失[ 1]。Animal Model:12 weeks, 25 g, Male C57BL/6 J mice (6-OHDA intoxication model)
Dosage:30 mg/kg
Administration:P.o.; daily for 21 days (commencing 3 days following induction of lesion)
Result:Prevented neuronal loss following 6-OHDA, preserving up to 75% of the SNpc neurons remaining (both Nissl and tyrosine hydroxylase (TH) positive neurons) after the initial phase of cell death.
Animal Model:12 weeks, 25 g, Male C57BL/6 J mice (MPTP model)
Dosage:1, 3, 10, 30, 80 mg/kg
Administration:P.o.; daily for 21 days (commenced 24?h after induction of lesion)
Result:Increased the proportion of SNpc cells rescued, increased there was a trend to improved turning behavior, significantly increased varicosity abundance, prevented the decline in levels of the presynaptic marker synaptophysin (SYNP) in a dose-dependent manner.
体外研究：
PBT434 methanesulfonate (0-20 μM；3 小时) 显着抑制铁产生的 H2O2，并显着降低 Fe 介导的 α-突触核蛋白聚集速率。PBT434 methanesulfonate (0-100 μM; 24 h) 对脑微血管内皮细胞没有细胞毒性作用。PBT434 methanesulfonate (20 μM; 24 h) 增加 hBMVEC 中总 TfR、Cp 蛋白水平的表达。
PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD).
体内研究：
PBT434 methanesulfonate (30 mg/kg；口服；每日一次，持续 21 天) 显着保留了 6-OHDA 毒模型中的神经元数量，并在 L-DOPA 模型中显示出明显更少的旋转，显着减少了 MPTP 模型中的 SNpc 神经元损失[ 1]。Animal Model:12 weeks, 25 g, Male C57BL/6 J mice (6-OHDA intoxication model)
Dosage:30 mg/kg
Administration:P.o.; daily for 21 days (commencing 3 days following induction of lesion)
Result:Prevented neuronal loss following 6-OHDA, preserving up to 75% of the SNpc neurons remaining (both Nissl and tyrosine hydroxylase (TH) positive neurons) after the initial phase of cell death.
Animal Model:12 weeks, 25 g, Male C57BL/6 J mice (MPTP model)
Dosage:1, 3, 10, 30, 80 mg/kg
Administration:P.o.; daily for 21 days (commenced 24?h after induction of lesion)
Result:Increased the proportion of SNpc cells rescued, increased there was a trend to improved turning behavior, significantly increased varicosity abundance, prevented the decline in levels of the presynaptic marker synaptophysin (SYNP) in a dose-dependent manner.
体外研究：
PBT434 methanesulfonate (0-20 μM；3 小时) 显着抑制铁产生的 H2O2，并显着降低 Fe 介导的 α-突触核蛋白聚集速率。PBT434 methanesulfonate (0-100 μM; 24 h) 对脑微血管内皮细胞没有细胞毒性作用。PBT434 methanesulfonate (20 μM; 24 h) 增加 hBMVEC 中总 TfR、Cp 蛋白水平的表达。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备